Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a ...

The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...

Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...

A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

bioAffinity's technology platform is successfully used with its commercial test, CyPath® Lung, a noninvasive diagnostic test for lung cancer that has demonstrated high sensitivity and specificity for ...

New research from National Jewish Health suggests that long-acting beta-agonists (LABAs), commonly used in combination asthma ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Please provide your email address to receive an email when new articles are posted on . The new diagnoses rates for COPD and asthma in the first year of the COVID-19 pandemic were lower than the ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Asthma can affect people of any age, in any location, and of any heritage. Although an elevated prevalence of asthma is notable in higher income countries such as the United States, Australia and the ...